ClinGen CDH1 specifications for the ACMG/AMP guidelines: improvement of germline variant clinical assertions and updated curation guidelines
Xi LuoiD, Jamie L. MaciaszekiD, Bryony A. ThompsoniD, Huei San Leong, Katherine DixoniD, Sónia Sousa, Michael Anderson, Maegan E. RobertsiD, Kristy LeeiD, Amanda B. SpurdleiD, Arjen R. MensenkampiD, Terra Brannan, Carolina Pardo, Liying ZhangiD, Tina F. PesaraniD, Sainan WeiiD, Grace‐Ann FasayeiD, Chimene A. KesserwaniD, Brian H. ShirtsiD, Jeremy L. DavisiD, Carla OliveíraiD, Sharon E. PloniD, Kasmintan A. SchraderiD, Rachid KaramiD
Abstract
PurposeThe Clinical Genome Resource (ClinGen) CDH1 Variant Curation Expert Panel (VCEP) developed specifications for CDH1 variant curation with a goal to resolve variants of uncertain significance (VUS) and with ClinVar conflicting interpretations for effective medical care. In addition, the CDH1 VCEP continues to update these specifications in keeping with evolving clinical practice and variant interpretation guidelines. MethodsCDH1 variant classification specifications were modified based on updated genetic testing clinical criteria, new recommendations from ClinGen, and expert knowledge from ongoing CDH1 variant curations. Trained biocurators curated 273 variants using updated CDH1 interpretation guidelines and incorporated published and unpublished data provided by diagnostic laboratories. All variants were reviewed by the ClinGen VCEP and classifications submitted to ClinVar. ResultsUpdated CDH1-specific variant interpretation guidelines include eleven major modifications since the initial specifications from 2018. Using the refined guidelines, 97% (36/37) of variants with ClinVar conflicting interpretations were resolved into benign, likely benign, likely pathogenic, or pathogenic, and 35% (15/43) of VUS were resolved into benign or likely benign. Overall, 88% (239/273) of curated variants had non-VUS classifications. ConclusionThe development and evolution of CDH1-specific criteria by the expert panel results in decreased uncertain and conflicting interpretations of variants in this clinically actionable gene.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- Organism
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- ClinGen Variant Curation Interface: A Variant Classification Platform for the Application of Evidence Criteria from ACMG/AMP Guidelines
Christine G. Preston, Matt W. Wright, … Helio A. Costa·Genome MedicinePeer-reviewed·Jan 17, 2022
- Disease-specific ACMG/AMP guidelines improve sequence variant interpretation for hearing loss
Mayher J. Patel, Marina T. DiStefano, … Kejian Zhang·Genetics in MedicinePeer-reviewed·Jul 6, 2021
- Multi-Platform Curation in the Development of ACMG/AMP Specifications for Von Hippel Lindau (VHL) Disease
Deborah Ritter, Chansonette Badduke, … Raymond H. Kim·Genetics in MedicinePeer-reviewed·May 1, 2026
- The ClinGen Severe Combined Immunodeficiency Disease Variant Curation Expert Panel: Specifications for classification of variants in ADA, DCLRE1C, IL2RG, IL7R, JAK3, RAG1, and RAG2
Vanessa Cristina Jacovas, Michelle Zelnick, … Xinrui Shi·Genetics in MedicinePeer-reviewed·Oct 15, 2025
- Specifications of the ACMG/AMP variant curation guidelines for the analysis of germline ATM sequence variants
Marcy E. Richardson, Megan A. Holdren, … Fergus J. Couch·medRxiv·May 28, 2024
- Comparative analysis of functional assay evidence use by ClinGen Variant Curation Expert Panels
Dona Kanavy, Shannon M. McNulty, … Jonathan S. Berg·Genome MedicinePeer-reviewed·Nov 29, 2019